Stockholders’ Equity (Tables)

9 Months Ended

Sep. 30, 2021

Equity [Abstract]

Schedule of Stock Options Activity

The following table summarizes stock options activity during the nine months ended September 30, 2021 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Award (in thousands, except per share data): 

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Total Intrinsic Value
Outstanding as of January 1, 2021		3,795		$	2.21		3.4	$	26,441
Granted		1,450			7.48		5.0		-
Forfeited		(398	)		8.32		-		-
Outstanding as of September 30, 2021		4,847		$	3.15		3.5	$	12,559
Options vested and exercisable		3,829		$	2.46		2.7	$	12,012

Summary of Weighted Average Assumptions Used In Determining Fair Value of Options

The aggregate weighted average grant date fair value for the options granted during the three and nine months ended September 30, 2021 was approximately $2.7 and $4.7 million, respectively. The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant for the nine months ended September 30, 2021:

	For the nine months ended
	September 30, 2021
Exercise price	$	7.48
Expected term (years)		3.9
Expected stock price volatility		80	%
Risk-free rate of interest		0.7	%
Expected dividend yield (per share)		0	%

Schedule of Warrant Activity

The following table summarizes warrant activities during the nine months ended September 30, 2021 (in thousands, except per share data).

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2021		450		$	3.22		2.7
Warrants granted		455			12.83		3.0
Cashless exercise		(50	)		5.00		-
Outstanding as of September 30, 2021		855		$	8.23		2.1
Warrants vested and exercisable		805		$	8.56		2.1

Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants

The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant for the nine months ended September 30, 2021:

	For the nine months ended
	September 30, 2021
Exercise price	$	12.83
Expected term (years)		3.0
Expected stock price volatility		81	%
Risk-free rate of interest		0.2	%
Expected dividend yield (per share)		0	%